Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations

YuSeun Kim, Jang Il Moon, Soon Il Kim, Kiil Park

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background. According to a pooled analysis of three randomized clinical studies concerning the prevention of acute rejection in cadaveric renal transplantation, mycophenolate mofetil (MMF) proved superior to azathioprine or placebo in conjunction with cyclosporine (CsA) and steroids. MMF-treated patients showed reduced incidence and severity of acute rejection, similar graft survival, and better graft function over 12 months. However, the multicenter trials did not include the Asian recipients of living donor kidneys. Methods. To assess the efficacy of MMF as the third component of a triple therapy in addition to CsA-Neoral and steroids in living donor renal transplantation recipients in Asians, a total of 100 recipients were randomized to receive CsA-Neoral and steroids (control group, n = 50), or MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, MMF group, n = 50). The dosing plan for Neoral and steroids was essentially same between groups. During 12 months of follow-up, we compared the incidence of acute rejection, adverse events such as infections, and 12-month actual graft and patient survival. Results. The graft and patient survival at 1 year was excellent in both groups: 96/98% in the control group and 98/100% in the MMF group, respectively. MMF significantly reduced the proportion of patients with at least one episode of acute rejection (34% in the control group vs. 14% in the MMF group), cumulative incidence of acute rejection episodes (46% vs. 16%), and requirement of antilymphocyte antibody (21.7% vs. 12.5%). In the MMF group, viral infection such as herpes zoster or chicken pox was more prevalent than in the control group. Conclusions. Like cadaveric renal transplantation, this open clinical trial showed MMF to be effective in reducing the incidence and severity of acute rejection if used in conjugation with Neoral and steroids after living donor renal transplantation in Asian ethnicity.

Original languageEnglish
Pages (from-to)578-581
Number of pages4
JournalTransplantation
Volume68
Issue number4
DOIs
Publication statusPublished - 1999 Aug 27

Fingerprint

Mycophenolic Acid
Living Donors
Kidney Transplantation
Incidence
Cyclosporine
Steroids
Graft Survival
Therapeutics
Control Groups
Antilymphocyte Serum
Chickenpox
Azathioprine
Herpes Zoster
Virus Diseases
Multicenter Studies

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

@article{b1ba9731caae4f01bb61ccb34bf207c2,
title = "Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations",
abstract = "Background. According to a pooled analysis of three randomized clinical studies concerning the prevention of acute rejection in cadaveric renal transplantation, mycophenolate mofetil (MMF) proved superior to azathioprine or placebo in conjunction with cyclosporine (CsA) and steroids. MMF-treated patients showed reduced incidence and severity of acute rejection, similar graft survival, and better graft function over 12 months. However, the multicenter trials did not include the Asian recipients of living donor kidneys. Methods. To assess the efficacy of MMF as the third component of a triple therapy in addition to CsA-Neoral and steroids in living donor renal transplantation recipients in Asians, a total of 100 recipients were randomized to receive CsA-Neoral and steroids (control group, n = 50), or MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, MMF group, n = 50). The dosing plan for Neoral and steroids was essentially same between groups. During 12 months of follow-up, we compared the incidence of acute rejection, adverse events such as infections, and 12-month actual graft and patient survival. Results. The graft and patient survival at 1 year was excellent in both groups: 96/98{\%} in the control group and 98/100{\%} in the MMF group, respectively. MMF significantly reduced the proportion of patients with at least one episode of acute rejection (34{\%} in the control group vs. 14{\%} in the MMF group), cumulative incidence of acute rejection episodes (46{\%} vs. 16{\%}), and requirement of antilymphocyte antibody (21.7{\%} vs. 12.5{\%}). In the MMF group, viral infection such as herpes zoster or chicken pox was more prevalent than in the control group. Conclusions. Like cadaveric renal transplantation, this open clinical trial showed MMF to be effective in reducing the incidence and severity of acute rejection if used in conjugation with Neoral and steroids after living donor renal transplantation in Asian ethnicity.",
author = "YuSeun Kim and Moon, {Jang Il} and Kim, {Soon Il} and Kiil Park",
year = "1999",
month = "8",
day = "27",
doi = "10.1097/00007890-199908270-00023",
language = "English",
volume = "68",
pages = "578--581",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. / Kim, YuSeun; Moon, Jang Il; Kim, Soon Il; Park, Kiil.

In: Transplantation, Vol. 68, No. 4, 27.08.1999, p. 578-581.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations

AU - Kim, YuSeun

AU - Moon, Jang Il

AU - Kim, Soon Il

AU - Park, Kiil

PY - 1999/8/27

Y1 - 1999/8/27

N2 - Background. According to a pooled analysis of three randomized clinical studies concerning the prevention of acute rejection in cadaveric renal transplantation, mycophenolate mofetil (MMF) proved superior to azathioprine or placebo in conjunction with cyclosporine (CsA) and steroids. MMF-treated patients showed reduced incidence and severity of acute rejection, similar graft survival, and better graft function over 12 months. However, the multicenter trials did not include the Asian recipients of living donor kidneys. Methods. To assess the efficacy of MMF as the third component of a triple therapy in addition to CsA-Neoral and steroids in living donor renal transplantation recipients in Asians, a total of 100 recipients were randomized to receive CsA-Neoral and steroids (control group, n = 50), or MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, MMF group, n = 50). The dosing plan for Neoral and steroids was essentially same between groups. During 12 months of follow-up, we compared the incidence of acute rejection, adverse events such as infections, and 12-month actual graft and patient survival. Results. The graft and patient survival at 1 year was excellent in both groups: 96/98% in the control group and 98/100% in the MMF group, respectively. MMF significantly reduced the proportion of patients with at least one episode of acute rejection (34% in the control group vs. 14% in the MMF group), cumulative incidence of acute rejection episodes (46% vs. 16%), and requirement of antilymphocyte antibody (21.7% vs. 12.5%). In the MMF group, viral infection such as herpes zoster or chicken pox was more prevalent than in the control group. Conclusions. Like cadaveric renal transplantation, this open clinical trial showed MMF to be effective in reducing the incidence and severity of acute rejection if used in conjugation with Neoral and steroids after living donor renal transplantation in Asian ethnicity.

AB - Background. According to a pooled analysis of three randomized clinical studies concerning the prevention of acute rejection in cadaveric renal transplantation, mycophenolate mofetil (MMF) proved superior to azathioprine or placebo in conjunction with cyclosporine (CsA) and steroids. MMF-treated patients showed reduced incidence and severity of acute rejection, similar graft survival, and better graft function over 12 months. However, the multicenter trials did not include the Asian recipients of living donor kidneys. Methods. To assess the efficacy of MMF as the third component of a triple therapy in addition to CsA-Neoral and steroids in living donor renal transplantation recipients in Asians, a total of 100 recipients were randomized to receive CsA-Neoral and steroids (control group, n = 50), or MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, MMF group, n = 50). The dosing plan for Neoral and steroids was essentially same between groups. During 12 months of follow-up, we compared the incidence of acute rejection, adverse events such as infections, and 12-month actual graft and patient survival. Results. The graft and patient survival at 1 year was excellent in both groups: 96/98% in the control group and 98/100% in the MMF group, respectively. MMF significantly reduced the proportion of patients with at least one episode of acute rejection (34% in the control group vs. 14% in the MMF group), cumulative incidence of acute rejection episodes (46% vs. 16%), and requirement of antilymphocyte antibody (21.7% vs. 12.5%). In the MMF group, viral infection such as herpes zoster or chicken pox was more prevalent than in the control group. Conclusions. Like cadaveric renal transplantation, this open clinical trial showed MMF to be effective in reducing the incidence and severity of acute rejection if used in conjugation with Neoral and steroids after living donor renal transplantation in Asian ethnicity.

UR - http://www.scopus.com/inward/record.url?scp=0000749074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000749074&partnerID=8YFLogxK

U2 - 10.1097/00007890-199908270-00023

DO - 10.1097/00007890-199908270-00023

M3 - Article

C2 - 10480420

AN - SCOPUS:0000749074

VL - 68

SP - 578

EP - 581

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -